Leader: Isabelle Bourdel-Marchasson
Diabetes mellitus is an ageing-related disease concerning in Europe about 15% of older people. Heterogeneity in health status (from robustness to dependency) and metabolism impairments (insulin resistance, insulin secretion failure, nutritional troubles) is very high. The complexity is even higher when considering comorbidity and social factors. The challenge we are facing is adaptation; we have to find the adequate care for a given subject with shared objectives considering diabetes in the frame of general health. The aim is to care the patient with diabetes and not only the diabetes of the patient. Two directions for work are ahead of us: the implementation of current guidelines and the production of evidences to improve to care the older people with diabetes.
One meta analysis of clinical trials investigating the effects of Acetyl-L-carnitine in geriatric diabetic neuropathy.
Projects & Events 2017, 2018
Action 1 - Education:
- Multi language multi-cultural education for older patients with diabetes and professionals.
- Education is a challenging task. Education has to be built to address the needs of professionals, patients and their support.
- We aim to construct Multilanguage educational material directed toward professionals. We will take advantage of this network to build future research studies to support the evolution of guidelines.
- First task: producing the educational material in English
- Second task: training of the trainers
- Third task: deploying the educational program in each geographical area
Action 2 - Producing communications in the field of diabetes and geriatrics:
- Symposia in geriatric congress:
Main topic: nutrition. The composition of the group allows a comprehensive work in the field of nutrition (malnutrition, inflammation, oxidative stress, supplements, nutrition in frail or dependent subject, quality of care, education).
- Practical clinical guide in diabeto-geriatrics
Next meeting of the group
EUGMS 2017 Congress in Nice, France
Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis. European Geriatric Medicine, Volume 8, Issue 2, April 2017, Pages 117-122. N. Veronese, G. Sergi, B. Stubbs, the EUGMS special interest group on diabetes, I. Bourdel-Marchasson, D. Tessier, C. Sieber, T. Strandberg, S. Gillain, M. Barbagallo, G. Crepaldi, S. Maggi, E. Manzato
- Andrej Zeyfang (Germany)
- Cornel Sieber (Germany)
- Daniel Tessier (Canada)
- Giuseppe Sergi (University of Padova, Italy)
- Isabelle Bourdel-Marchasson (France)
- Marina Kotsani (France)
- Nicola Veronese (Italy)
- Sophie Gillain (Belgium)
- Stefania Maggi (Italy)
- Timo Strandberg (Finland)
Sigma-tau is a pharmaceutical company founded in Italy in 1957; now is a company of ALFASIGMA Group with an important national and international presence. Acetyl-L-Carnitine (ALC) is a product developed by Sigma-tau and marketed in Italy. ALC supplementation induces neuroprotective, neurotrophic and analgesic effects in the peripheral nervous system. In a recent review and meta-analysis, ALC appears to be effective in reducing pain due to diabetic neuropathy compared to active or placebo controls and improving electromyographic parameters in these patients. ALC seems to be useful also in other geriatric diseases, like depression and other peripheral neuropathies.
In the next EUGMS Congress (September 2017, Nice) is planned a symposium about the recent molecular and clinical data on ALC.